{
  "docId": "019de072-0fef-7225-bee8-4eafefc8a1ee",
  "docSlug": "7f14a86c142f5693f0e80c8dcf59a0d2",
  "documentTitle": "23andMe | Investor Presentation Deck | 63 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 63,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide outlines a standard clinical trial design including patient criteria, cohort structure (Part A/B), and primary/secondary objectives.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0fef-7225-bee8-4eafefc8a1ee/47",
  "deckHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee",
  "deckJsonHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee.json",
  "deckAnchorHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.27
      },
      "kind": "diagram",
      "text": "Study Design",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4567f60d-56be-49d2-a0bf-b75f5bdce226",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a7d22a4-d976-4a8f-b660-ed6b85ea9260",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.27
      },
      "kind": "list",
      "text": "Objectives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c899894b-a9a9-46ca-a322-325701cf3490",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3b0a7b1-9592-42c8-add9-452c9c6ba866",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "41259c2d-9945-47b3-b0d4-72c4412bbd85",
      "evidence": "The slide presents a study with a clear objective, study design, and components, which aligns with the SCQA framework.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "2cb5f744-5613-495b-9c08-f67aca51a316",
      "evidence": "Standardized structure for Phase 1 study methodology",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}